On February 1, 2002, Judge Thomas F. Hogan of the United States District Court for the District of Columbia signed an order in the matter of In re: Lorazepam and Clorazepate Antitrust Litigation, MDL Docket No. 1290, finally approving settlements of two antitrust class actions filed on behalf third-party payors who overpaid for two anti-anxiety drugs from 1998 through 1999. The settlements established two funds totaling $35.4 million payable to third-party payors throughout the United States. Bernard Persky and Hollis Salzman, the Labaton Sucharow attorneys who spearheaded the litigation, served as Co-Lead Counsel for the third-party payor plaintiffs in both class actions. These settlements cover insurers, union health and welfare funds and other third-party payors who paid for all or part of the costs of their members' or insureds' prescriptions of generic Lorazepam and Clorazepate. [Additional information can be obtained about this matter at the following internet website: www.tppsettlement.com].

In addition, Labaton Sucharow was Co-Lead Counsel in related antitrust litigation on behalf of consumers brought in conjunction with the Federal Trade Commission and the attorneys general of thirty-two states. This litigation was also settled at the same time, with Mylan paying $100 million, which will be used to reimburse consumers and state agencies in all fifty states and the District of Columbia for a portion of any overcharge they may have incurred when purchasing either or both drugs.